SCHEMBL9370934

SCHEMBL9370934

CCOC(=O)C1Cc2c(O)ccc(F)c2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
MAPK1 P28482 3/20 0.43
TSHR P16473 3/20 0.43
CYP1A2 P05177 1/20 0.43
HTR1A P08908 1/20 0.43
CYP2D6 P10635 1/20 0.43
DRD2 P14416 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
KDM4E B2RXH2 7/20 0.43
KMT2A Q03164 5/20 0.42
LMNA P02545 2/20 0.42
PMP22 Q01453 2/20 0.42
GLA P06280 1/20 0.42
APEX1 P27695 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30334623 1.00 ALDH1A1 (0.45) ALDH1A1MAPK1TSHRCYP1A2HTR1A
SCHEMBL23857269 0.92 ALDH1A1 (0.50) ALDH1A1MAPK1TSHRKDM4EKMT2A
SCHEMBL30047239 0.92 ALDH1A1 (0.50) ALDH1A1MAPK1TSHRKDM4EKMT2A
SCHEMBL30046661 0.81 ALDH1A1 (0.41) ALDH1A1MAPK1TSHRPKMKDM4E
SCHEMBL23856657 0.81 ALDH1A1 (0.41) ALDH1A1MAPK1TSHRPKMKDM4E
SCHEMBL30253311 0.80 ALDH1A1 (0.43) ALDH1A1MAPK1TSHRKDM4EKMT2A
SCHEMBL23856872 0.80 ALDH1A1 (0.43) ALDH1A1MAPK1TSHRKDM4EKMT2A
SCHEMBL23856566 0.78 KDM4E (0.48) ALDH1A1MAPK1TSHRDRD2KDM4E
SCHEMBL30049087 0.78 KDM4E (0.48) ALDH1A1MAPK1TSHRDRD2KDM4E
SCHEMBL3947526 0.78 GAA (0.47) ALDH1A1MAPK1TSHRKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2024-08-01 US disclosed
US-20240252506-A1 COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2024-08-01 US disclosed
EP-4405352-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2024-07-31 EP disclosed
CN-117980303-A Novel compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-05-03 CN disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
WO-2023041756-A1 NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2023-03-23 WO disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 EP disclosed
CN-115298176-A Compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2022-11-04 CN disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed
EP-0425946-B1 Iso- and heterocyclic phenylsulphonamides BAYER AG (DE) 1994-08-17 EP disclosed
US-5264458-A Antithrombotic iso- and heterocyclic phenylsulphonamides BAYER AKTIENGESELLSCHAFT (DE) 1993-11-23 US disclosed
US-5191092-A ANTITHROMBOTIC ISO- AND HETEROCYCLIC PHENYLSULPHONAMIDES BAYER AKTIENGESELLSCHAFT (DE) 1993-03-02 US disclosed
EP-0425946-A2 Iso- and heterocyclic phenylsulphonamides BAYER AG (DE) 1991-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254140-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION C3AR1, LTB4R, C5 ALDH1A1 681/4885MAPK1 2283/4885TSHR 1801/4885
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION LTB4R, C5, C3AR1 ALDH1A1 842/4885MAPK1 2069/4885TSHR 1921/4885
US-20240252506-A1 COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION C3AR1, LTB4R, C5 ALDH1A1 630/4885MAPK1 1953/4885TSHR 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.